Therapeutic regimen with darolutamide for metastatic castration resistant prostate cancer: a case report
10.3760/cma.j.cn112330-20220401-00157
- VernacularTitle:达罗他胺治疗转移性去势抵抗性前列腺癌1例报告
- Author:
Zhien ZHOU
1
;
Ming ZHU
;
Yi ZHOU
;
Weigang YAN
Author Information
1. 中国医学科学院北京协和医学院北京协和医院泌尿外科，北京 100730
- Keywords:
Prostatic neoplasms;
Carcinoma;
Metastatic;
Castration resistant;
Darolutamide
- From:
Chinese Journal of Urology
2022;43(7):545-547
- CountryChina
- Language:Chinese
-
Abstract:
There are few studies about the treatment of metastatic castration-resistant prostate cancer (mCRPC) with darolutamide. This paper reports a case that an 83-year-old patient complained of dysuria. His initial diagnosis was metastatic hormone sensitive prostate cancer(mHSPC). Androgen deprivation therapy (ADT) plus bicalutamide was performed. Re-examination of bone scan after half a year revealed that there were more than two new bone metastases, which was considered entering mCRPC. Due to the patient’s advanced age, post medical history of epilepsy, type 2 diabetes and cardiac radiofrequency ablation, long-term use of phenobarbital and repaglinide, the therapy was changed to ADT plus darolutamide to avoid drug contraindications. Re-examination of bone scan after 10 months revealed decreased metabolism in some metastases, and tPSA declined continuously.
